Eco Animal Health gets marketing authorisations in US and Canada
Eco Animal Health Group announced on Wednesday that it has received marketing authorisations from the United States Center for Veterinary Medicine of the Food and Drug Administration (FDA) and from the Veterinary Drugs Directorate of Health Canada, for its ‘Aivlosin’ product.
The AIM-traded firm said the approvals of Aivlosin water soluble granules added mMycoplasma hyopneumoniae to the list of pathogens indicated for the control of swine respiratory disease (SRD).
It said M. hyopneumoniae is a primary pathogen in swine respiratory disease complexes, playing an important role in facilitating the entry of bacterial and viral pathogens.
SRD occurs worldwide, and causes major economic losses to the pig industry.
Eco Animal Health said Aivlosin water soluble granules were under the control of veterinarians in the North American market, and was only available under prescription.
It said it had a low, highly-effective dose rate, short treatment duration and a zero-day drug withholding period.
The product would be marketed through Pharmgate Animal Health, the group's sales and marketing joint operation with US-based Pharmgate.
“We are delighted to receive this significant marketing authorisation for Aivlosin water soluble granules in the US and in Canada, which are among the most important pork producing and exporting countries in the world,” said chief executive officer Marc Loomes.
“M. hyopneumoniae plays a pivotal role in the important SRD segment and its control is frequently considered by swine producers to be one of the most important issues they face today.”
At 1227 GMT, shares in Eco Animal Health were up 0.41% at 247.5p.